MedLife, Romania’s leading private healthcare provider, has launched Longevity 100+, the first large-scale genetic testing programme in the country and the region. The initiative aims to support a national shift from reactive to preventive and personalised medicine by integrating advanced genetic testing, data analytics, and medical counselling.
The project offers free access to advanced Low-Pass Whole Genome Sequencing (LP-WGS) testing for 4,000 employees from MedLife, BCR, World Class, and Decathlon, with the potential to expand to other companies. The results will underpin Romania’s first comprehensive study of the genetic characteristics of the active population, supporting the development of prevention strategies and personalised healthcare. The project is fully funded by MedLife from its own resources.
Each participant will take a genetic test processed on the Illumina NovaSeq X Plus platform, recently acquired by MedLife as a national first. Results will be reviewed by a medical geneticist who will provide individual counselling and tailored recommendations. All participants will also have access to the MedLife app, which integrates historical lab and imaging data with genomic findings to create personalised health plans.
“We are at a turning point in how we approach health. Artificial intelligence and medical technologies open new opportunities, and Longevity 100+ aims to democratise access to genetic testing — moving from treatment after illness to early risk identification,” said Mihai Marcu, CEO & Chairman of MedLife Group.
The Longevity 100+ test identifies over 100 genetic predispositions, including 75 common diseases such as cancer, metabolic, cardiovascular, autoimmune, and neurological disorders. It also provides insights into lifestyle-related factors, including nutrition, physical activity, and stress response.
“This is a paradigm shift in medicine. The new test can reveal predispositions to chronic diseases and provide practical recommendations for prevention and long-term health,” said Dr. Dumitru Jardan, Head of the MedLife Molecular Biology Laboratory.
The initiative is supported by a multidisciplinary team of 20 specialists in genetics, bioinformatics, and preventive medicine. To manage and protect data, MedLife collaborates with Ipsos and D&B David and Baias, PwC’s correspondent law firm in Romania.
“The results of the Longevity 100+ tests are confidential and accessible only to patients during consultations with geneticists. Employers, insurers, or third parties cannot access them,” added Mihai Marcu.
MedLife plans to use the project’s findings to build Romania’s first genetic map, identifying health risk patterns in the population. The company sees this as a foundation for future research and public health policies focused on prevention and quality of life.
